CN108779158A - 热稳定性fgf2多肽、其用途 - Google Patents

热稳定性fgf2多肽、其用途 Download PDF

Info

Publication number
CN108779158A
CN108779158A CN201680076784.3A CN201680076784A CN108779158A CN 108779158 A CN108779158 A CN 108779158A CN 201680076784 A CN201680076784 A CN 201680076784A CN 108779158 A CN108779158 A CN 108779158A
Authority
CN
China
Prior art keywords
fgf2
amino acid
polypeptide
cells
thermostable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680076784.3A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·德沃夏克
帕维尔·克雷奇
卢卡斯·巴莱克
利维亚·艾塞利奥娃
赞尼塔·科尼卡
帕维尔·德沃夏克
戴维·贝德纳
简·布列佐夫斯基
伊娃·塞贝斯多瓦
拉德卡·查卢普科娃
维罗尼卡·斯蒂芬科娃
帕维尔·瓦纳塞克
茨比尼克·普罗科普
吉里·达姆博斯基
米歇尔·博萨科娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
N & D Co Ltd
MASARYK UNIVERSITY
Original Assignee
N & D Co Ltd
MASARYK UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N & D Co Ltd, MASARYK UNIVERSITY filed Critical N & D Co Ltd
Publication of CN108779158A publication Critical patent/CN108779158A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
CN201680076784.3A 2015-11-27 2016-10-03 热稳定性fgf2多肽、其用途 Pending CN108779158A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802 2015-11-27
EP15196802.1 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (1)

Publication Number Publication Date
CN108779158A true CN108779158A (zh) 2018-11-09

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680076784.3A Pending CN108779158A (zh) 2015-11-27 2016-10-03 热稳定性fgf2多肽、其用途

Country Status (13)

Country Link
US (1) US11746135B2 (enExample)
EP (1) EP3380508B1 (enExample)
JP (1) JP7131772B2 (enExample)
KR (1) KR102650035B1 (enExample)
CN (1) CN108779158A (enExample)
AU (1) AU2016359722B2 (enExample)
BR (1) BR112018010676A2 (enExample)
CA (1) CA3006388C (enExample)
ES (1) ES2824479T3 (enExample)
LT (1) LT3380508T (enExample)
PL (1) PL3380508T3 (enExample)
SG (1) SG11201804402WA (enExample)
WO (1) WO2017089016A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531A (zh) * 2019-06-19 2021-01-08 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
CN114746436A (zh) * 2019-11-25 2022-07-12 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210087525A1 (en) * 2019-09-19 2021-03-25 Northwestern University Cost effective culture media and protocol for human induced pluripotent stem cells
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
CN120265649A (zh) * 2022-11-25 2025-07-04 比特乐健康保健股份公司 稳定性提高的fgf-2多肽、制备fgf-2多肽的方法及其用途
KR20240173282A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
KR20240173283A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
US6083706A (en) * 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
WO2004069298A1 (en) * 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
CN103597076A (zh) * 2011-03-01 2014-02-19 人体酶公司 成纤维细胞生长因子的热稳定变体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7816140B2 (en) * 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
EP2083846B1 (en) * 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
EP4202040A1 (en) 2010-07-01 2023-06-28 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
WO2013082196A1 (en) 2011-11-28 2013-06-06 The Regents Of The University Of California bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF
US8772460B2 (en) 2011-12-16 2014-07-08 Wisconsin Alumni Research Foundation Thermostable FGF-2 mutant having enhanced stability
US9023644B2 (en) 2011-12-16 2015-05-05 Wisconsin Alumni Research Foundation FGF having enhanced stability
US9474785B2 (en) * 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181B1 (en) * 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
US6083706A (en) * 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
WO2004069298A1 (en) * 2003-02-06 2004-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
CN103597076A (zh) * 2011-03-01 2014-02-19 人体酶公司 成纤维细胞生长因子的热稳定变体

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531A (zh) * 2019-06-19 2021-01-08 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
CN112190531B (zh) * 2019-06-19 2022-11-01 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
CN114746436A (zh) * 2019-11-25 2022-07-12 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
CN114746436B (zh) * 2019-11-25 2024-07-02 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
US12103953B2 (en) 2019-11-25 2024-10-01 Korea Institute Of Ocean Science Technology FGF2 polypeptide with improved temperature stability and protease resistance and use thereof
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法

Also Published As

Publication number Publication date
PL3380508T3 (pl) 2021-07-12
WO2017089016A1 (en) 2017-06-01
JP2019500414A (ja) 2019-01-10
SG11201804402WA (en) 2018-06-28
EP3380508B1 (en) 2020-07-22
CA3006388A1 (en) 2017-06-01
ES2824479T3 (es) 2021-05-12
KR102650035B1 (ko) 2024-03-20
AU2016359722B2 (en) 2020-09-17
BR112018010676A2 (pt) 2019-04-09
CA3006388C (en) 2023-05-09
US11746135B2 (en) 2023-09-05
US20200270320A1 (en) 2020-08-27
JP7131772B2 (ja) 2022-09-06
EP3380508A1 (en) 2018-10-03
KR20180080335A (ko) 2018-07-11
LT3380508T (lt) 2020-11-10

Similar Documents

Publication Publication Date Title
CN108779158A (zh) 热稳定性fgf2多肽、其用途
AU2016359722A1 (en) Thermostable FGF2 polypeptide, use thereof
Yayon et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
Logsdon et al. The IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-linked glycosylation
US8772460B2 (en) Thermostable FGF-2 mutant having enhanced stability
Campbell et al. The solution structures of epidermal growth factor and transforming growth factor alpha
CN116333094B (zh) 一种重组人源化I型胶原蛋白α1及表达载体和应用
D'Ambrosio et al. Probing the dimeric structure of porcine aminoacylase 1 by mass spectrometric and modeling procedures
CN118955691A (zh) 重组人源化xvii型胶原蛋白及其制备方法和应用
US11746134B2 (en) Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof
Parry et al. Molecular structure of sauropsid β-keratins from tuatara (Sphenodon punctatus)
Bernard-Pierrot et al. Glycosaminoglycans promote HARP/PTN dimerization
JPWO1993003061A1 (ja) 造血幹細胞増加剤
CN107012150A (zh) 重组人成纤维细胞生长因子‑16的克隆、表达和应用及其生物学活性的测定方法
CN116693626A (zh) 订书肽及其用途和在体外扩增干细胞的方法
JP5882198B2 (ja) ラミニン５を含んだ系で細胞を培養する方法
US20250353888A1 (en) Thermostable FGF10 Polypeptide or Fragment Thereof and Use Thereof
Liu et al. Computer-assisted engineering of stable human leukemia inhibitory factor
Okada et al. Developing FGF2 Mutants with Selectively Reduced Heparan Sulfate Affinity to Explore their Impact on FGFR1 Signaling
CZ309550B6 (cs) Termostabilní polypeptid na bázi FGF18 a jeho použití
CN120943935A (zh) 一种具有高活性的重组人源化ⅲ型胶原蛋白及其制备方法和应用
JP2024533113A (ja) ヒトビトロネクチン断片及びその使用
US20190135884A1 (en) Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof
EP3941932A1 (en) Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof
Power Design of antimicrobial peptide based on the heparin binding segment of FGF-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination